• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Ziopharm-Intrexon collaborate with Merck Serono

Ziopharm-Intrexon collaborate with Merck Serono

April 1, 2015
CenterWatch Staff

Ziopharm Oncology, a Boston, Mass.-based biotech company, and Intrexon, a synthetic biology provider, have announced their oncology programs will be strengthened through Intrexon's new global collaboration focused exclusively on novel chimeric antigen receptor T-cell (CAR-T) products with Merck Serono, the biopharmaceutical division of Merck. Intrexon will share the economic provisions of this collaboration, including upfront payment, milestones and royalties, equally with Ziopharm.

Merck Serono will elect CAR-T targets, two initially, for which it will provide certain research funding. Ziopharm will be responsible for any additional R&D expenditures. Once these candidates reach IND stage, the programs will be transferred to Merck Serono for clinical development and commercialization. Ziopharm and Intrexon also will independently conduct R&D on other CAR-T candidates, with Merck having the opportunity during clinical development to opt-in. Ziopharm's other oncology programs will continue through its exclusive channel collaboration (ECC) with Intrexon.

"Controlled CAR-T treatments hold the promise of delivering the powerful benefit of a targeted immune response to cancer with the ability to modulate immune toxicity, leading to safer, more efficacious treatments," said Jonathan Lewis, M.D., Ph.D., CEO of Ziopharm. "The collaboration with Merck Serono brings world-class resources to our development efforts that greatly enhance our ability to translate CAR-T therapies from bench to bedside."

"Harnessing the power of the immune system in a regulated manner is key to address the challenges of current CAR-T approaches and combat malignancies with adoptive cell therapies," said Gregory Frost Ph.D., senior vice president and head of Intrexon's health sector. "We believe our alliances with Merck Serono and Ziopharm will accelerate progress in our synthetic immuno-oncology pipeline and drive next-generation medicines to market."

Upcoming Events

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing